Von Hoff D D, Alberts D S, Mattox D E, Coulthard S, Dana B, Manning M, Myers J W, Griffin C B
Cancer Clin Trials. 1981;4(2):215-8.
Twenty-six patients with advanced head and neck cancer, 22 of whom had failed prior surgery and/or radiotherapy, were treated with a combination regimen of cis-diamminedichloroplatinum II, bleomycin, and methotrexate. There were no complete responses. Nine patients achieved a partial response (35%). Three of the four (75%) patients without prior therapy achieved a partial response while only 6 of the 22 patients (27%) with prior surgery and/or radiation therapy obtained a partial response. The median response duration was 3 months. Patients with a partial response did not live significantly longer than those who did not live significantly longer than those who did not respond. Toxic reactions were frequent: there were three episodes of sepsis secondary to leukopenia and two cases of bleomycin pulmonary toxicity. Mucositis was noted in 40% and nausea and vomiting in 60% of patients. We conclude that this triple-drug regimen has little value in the treatment of patients with advanced squamous cell carcinoma of the head and neck who have failed prior surgery and radiotherapy.
26例晚期头颈癌患者接受了顺铂II、博来霉素和甲氨蝶呤联合治疗方案,其中22例此前手术和/或放疗失败。无完全缓解病例。9例患者获得部分缓解(35%)。4例未接受过前期治疗的患者中有3例(75%)获得部分缓解,而22例接受过前期手术和/或放疗的患者中只有6例(27%)获得部分缓解。中位缓解持续时间为3个月。部分缓解的患者生存时间并未显著长于未缓解的患者。毒性反应频繁:有3例因白细胞减少继发败血症,2例出现博来霉素肺毒性。40%的患者出现粘膜炎,60%的患者出现恶心和呕吐。我们得出结论,对于此前手术和放疗失败的晚期头颈鳞状细胞癌患者,这种三联药物方案治疗价值不大。